The National Institute of Standards and Technology (NIST) has established a Vitamin D Metabolites Quality Assurance Program (VitDQAP) in collaboration with the National Institutes of Health (NIH) Office of Dietary Supplements. Participants in the tenth exercise of this program, the Winter 2015 Comparability Study, were asked to use the methodology of their choice to measure concentrations of 25-hydroxyvitamin D in pooled human serum control and study materials distributed by NIST. The study materials consisted of Standard Reference Material (SRM) 972a Vitamin D Metabolites in Frozen Human Serum Level 2 and VitDQAP-III (a material designed for the VitDQAP). SRM 968d Fat-Soluble Vitamins, Carotenoids, and Cholesterol in Human Serum Level 1 was provided as a control material. Participants provided their data to NIST, where it was compiled and evaluated for trueness relative to the NIST value and concordance within the participant community. A report of results was provided to all participants of the study, and laboratories were identified by code numbers known only to them. The results from this tenth study are reported along with a summary of the analytical methods used. ______________________________________________________________________________________________________ This publication is available free of charge from: http://dx.doi.org/10.6028/NIST.IR.8142
For SRM 972a L2 (Vial A), NIST determined 25(OH)D3 and 25(OH)D2 using both ID-LC-MS and the ID-LC-MS/MS RMP. The results for 25(OH)D3, 25(OH)D2, 25(OH)DTotal, and 3-epi-25(OH)D3 are a combination of results from the two NIST methods as well as a third method from the Centers for Disease Control and Prevention (CDC) and are certified values. A NIST certified value is a value for which NIST has the highest confidence in its accuracy in that all known or suspected sources of bias have been investigated or taken into account [3] . Detailed information about the characterization of SRM 972a and the components of the expanded uncertainty (U) may be found in the Certificate of Analysis, located on the NIST website [4] .
The NIST values for 25(OH)D3, 25(OH)D2, and 3-epi-25(OH)D3 in VitDQAP-III (Vial B) and SRM 968d L1 (Control) were determined solely with the ID-LC-MS/MS method. For VitDQAP-III (Vial B), the NIST values for 25(OH)D3, 25(OH)D2, and 3-epi-25(OH)D3 are reported with expanded uncertainties that incorporate components for measurement variability and measurement uncertainty associated with the density of the materials and the purity of the reference standards. In addition, the measurements include an additional 1 % type B uncertainty for unknown systematic errors, which is consistent with the practice used at NIST for clinical measurements [1] . For SRM 968d L1 (Control), the NIST values for 25(OH)D3 and 3-epi-25(OH)D3 are reported as described for VitDQAP-III (Vial B), but the value for 25(OH)D2 was well below the limit of quantitation and was estimated to be 0.1 ng/mL based on one measurement.
The NIST values for 25(OH)DTotal in VitDQAP-III (Vial B) and SRM 968d L1 (Control) are the sum of the individual values for 25(OH)D3 and 25(OH)D2, and the expanded uncertainties incorporate the measurement uncertainties for the two analytes.
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Results for 25(OH)DTotal
A summary of the individual participant data for total 25-hydroxyvitamin D (25(OH)DTotal) in SRM 972a L2 (Vial A), VitDQAP-III (Vial B), and SRM 968d L1 (Control) is provided in Table 1 .
The community results are summarized at the bottom of Table 1 for all reported methods, the IA methods only, the LC methods only, and the LC-MS n methods only. The community results include the total number of quantitative values reported (N), the median value for each analyte, the MADe (the median absolute deviation estimate, a robust estimate of the standard deviation), and the percent coefficient of variation (CV %). From the single reported values for all datasets for a given technique (IA or LC), the consensus median and the consensus expanded uncertainty (2  MADe) were determined. For both of the major techniques (IA or LC) in each figure, the solid lines () and () represent the consensus median, and the dashed lines (-----) and (-----) represent the consensus expanded uncertainty interval (median ± 2  MADe). The laboratories with results that fall between the two dashed lines are within the consensus range for their technique (IA or LC).
The red lines () in each figure (Figures 1 -3 ) represent the NIST value and its associated uncertainty (i.e., value ± U). NIST has confidence that the "true" value for each material lies within this interval. When these lines are not within the consensus ranges for each technique (IA or LC), then there may be method bias.
Specific results for each of the three study materials are summarized below. Note that the assessment is based on the actual reported values, not the lines and symbols, which have been enlarged to show detail and the laboratory number.
SRM 972a L2 (Vial A): Figure 1
 For the IA results, two reported values are outside of the consensus range (both CLIA).  For the LC results, three reported values are outside of the consensus range (two LC-MS n , one LC-UV).  The consensus median value for the IA results is slightly lower than the NIST expanded uncertainty range (red lines).  The consensus median value for the LC results is comparable to the NIST expanded uncertainty range (red lines).  The NIST expanded uncertainty range (red lines) falls within the consensus range for both IA and LC.
VitDQAP-III (Vial B): Figure 2
 For the IA results, five reported values are outside the consensus range (three CLIA, one EIA, and one RIA).  For the LC results, six reported values are outside the consensus range (five LC-MS n , one LC-UV).  The consensus median value for the IA results is lower than the NIST expanded uncertainty range (red lines).  The consensus median value for the LC results is slightly higher than the NIST expanded uncertainty range (red lines). ______________________________________________________________________________________________________ This publication is available free of charge from: http://dx.doi.org/10.6028/NIST.IR.8142  The NIST expanded uncertainty range (red lines) falls within the consensus ranges for both IA and LC.
SRM 968d L1 (Control): Figure 3
 For the IA results, five reported values are outside of the consensus range (four CLIA, one EIA).  For the LC results, five reported values are outside of the consensus range (three LC-MS n , two LC-UV).  The consensus median value for the IA results is higher than the NIST expanded uncertainty range (red lines).  The consensus median value for the LC results is comparable to the NIST expanded uncertainty range (red lines).  The NIST expanded uncertainty range (red lines) falls within the consensus range for both IA and LC. ______________________________________________________________________________________________________ This publication is available free of charge from: http://dx.doi.org/10.6028/NIST.IR.8142 In each plot, there are two blue consensus boxes, one for IA methods and one for LC methods (as indicated). Laboratory results that are within the consensus range for both study materials are within the blue consensus boxes. Conversely, laboratory results that fall outside of (or on the edge of) either of the consensus boxes are not included in the consensus ranges and are highlighted with their laboratory code numbers. In each plot, the NIST values for the materials are denoted with a red diamond symbol (), and the Youden line (y=x) centered on the NIST value is illustrated by a red line () across the magnitude of the y-axis and x-axis, respectively.
Specific results as assessed from the Youden comparison plots are summarized below.
SRM 972a L2 (Vial A) and VitDQAP-III (Vial B): Figure 4 a
 IA results that are not included in the consensus ranges include numbers 030a, 188, 261, 268b, and 274  LC results that are not included in the consensus ranges include numbers 060, 110, 119, 221c, 243a, 243b, 251, 270 , and 271  The Youden line runs through the center of both the IA and LC consensus boxes, illustrating that both the IA and LC results are in agreement with each other and with the NIST results for these materials.
VitDQAP-III (Vial B) and SRM 968d L1 (Control): Figure 4 b
 IA results that are not included in the consensus ranges include numbers 030a, 188, 198c, 214b, 261, 262, 268b , and 274  LC results that are not included in the consensus ranges include numbers 060, 110, 119, 150, 189, 221b, 221c, 225, and 270 The Youden line runs through the center of the LC consensus box and through the bottom corner of the IA consensus box, illustrating that the LC results are in better agreement with the NIST results than are the IA results for these materials. ______________________________________________________________________________________________________ 
Discussion of Results for 25(OH)DTotal
In the Winter 2015 comparability study, both SRM 972a L2 (Vial A) and SRM 968d L1 (Control) contain predominantly 25(OH)D3. The CV %'s of 9.1 % and 6.9 % (all methods) for SRM 972a L2 (Vial) A and SRM 968d L1 (Control), respectively, are consistent with participant performance for other materials containing predominantly 25(OH)D3 that were evaluated in previous comparability studies of the VitDQAP. The Winter 2015 exercise was the first to utilize study materials that were evaluated in previous comparability studies of the VitDQAP. VitDQAP-III (Vial B) was also evaluated in the Winter 2014 comparability study, and SRM 972a L2 (Vial A) was previously evaluated in Winter 2012. Table 2 provides the program results for each of these two study materials for the labs participating in the current study. Using the results in Table 2 , labs that participated in the prior studies could assess their performance for these materials over time. In addition, it is informative to compare the summary statistics at the bottom of Table 2 . For both materials, the median and CV % results are very consistent across both comparability studies in which the materials were evaluated, even though there are fewer labs and hence data points (N) for the prior studies. illustrates that there are not consistent within-laboratory biases for VitDQAP-III and SRM 972a L2 over 1 and 3 years, respectively, and that the within-round variability is consistent with the over-time variability. While the vast majority of labs yield results that are within the consensus boxes for their techniques, the labs that fall outside are not in as good statistical control. For VitDQAP-III, these labs include 030a, 060, 110, 119, 188, 251, 259 , and 261 (Figure 5a) , and for SRM 972a L2, these labs include 188, 189, 216, 228a, and 243a (Figure 5b) . ______________________________________________________________________________________________________ Table 3 .
The single reported values for 25(OH)D3 and 25(OH)D2 in VitDQAP-III (Vial B) are plotted in Figure 5 a and b, respectively. The results from LC-MS n and LC-UV were sorted separately, as indicated by the x-axis labels. In each plot, the consensus median is represented by the solid line (), and the expanded uncertainty interval (2  MADe), is represented by the dashed lines  (----) . The laboratories with results that fall between the two dashed lines are within the consensus variability range.
The red lines () in Figures 5 a and b represent the NIST value and its associated uncertainty (i.e., value ± U). NIST has confidence that the "true" value for each metabolite lies within this interval. When these lines are not within the consensus range, then there may be method bias. 
Dihydroxyvitamin D3 Metabolites
The Winter 2015 comparability study is the first in which a participant, Lab 269, reported results for two dihydroxyvitamin D3 metabolites, 24, 25-dihydroxyvitamin D3 (24,25(OH)2D3) and 1α, 25dihydroxyvitamin D3 (1α,25(OH)2D3), in each of the study materials. The results provided by participant 269 for these metabolites are provided in the following 
Conclusions from the Winter 2015 Comparability Study of the VitDQAP
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n/a = not applicable (for immunoassay methods); n/r = not reported or not determined; n/d = not detected; < X = less than a reported quantitation limit of X
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